Advances in Tumor Immunology and Immunotherapy (eBook)
IX, 371 Seiten
Springer New York (Verlag)
978-1-4614-8809-5 (ISBN)
Recent advances in understanding of fundamental immunology have created new insights into the dynamic interactions between tumors and the immune system. This includes new understanding of T- and B-cell interaction, immune inhibitory mechanisms including the biology of T regulatory cells, myeloid suppressor cells, and dendritic cell subsets.
Enhanced understanding of mechanisms underlying T-cell anergy such as arginine deprivation, immunosuppressive cytokines, defective innate and interferon response pathways, and NKG2D downregulation have all provided new insight into suppression of anti-tumor immunity and tumor evasion.
In addition to emerging understanding of tumor evasion, new immune targets such as CTLA4 blockade, NK stimulatory receptors, manipulation of the antigen processing and presentation, cytokine and costimulatory responses all provide new possibilities for enhancing anti-tumor immunity even in tumors previously felt to be resistant to immune attack. Several of these strategies have already been realized in the clinic. The volume will explore evolving paradigms in antigen presentation, dendritic cell biology, the innate response and immunosuppressive mechanisms, and emerging strategies for manipulation of the immune system for therapeutic benefit that have realized success in neuroblastoma, leukemia, melanoma, lung cancer, and allogeneic transplantation. Early successes as well as failures will be highlighted to provide a snapshot of the state of clinical immunotherapy with an eye to future possibilities such as combination therapies, adoptive T-cell transfer, and the retargeting of immune cells via T-cell receptor engineering.
Recent advances in understanding of fundamental immunology have created new insights into the dynamic interactions between tumors and the immune system. This includes new understanding of T- and B-cell interaction, immune inhibitory mechanisms including the biology of T regulatory cells, myeloid suppressor cells, and dendritic cell subsets. Enhanced understanding of mechanisms underlying T-cell anergy such as arginine deprivation, immunosuppressive cytokines, defective innate and interferon response pathways, and NKG2D downregulation have all provided new insight into suppression of anti-tumor immunity and tumor evasion. In addition to emerging understanding of tumor evasion, new immune targets such as CTLA4 blockade, NK stimulatory receptors, manipulation of the antigen processing and presentation, cytokine and costimulatory responses all provide new possibilities for enhancing anti-tumor immunity even in tumors previously felt to be resistant to immune attack. Several of these strategies have already been realized in the clinic. The volume will explore evolving paradigms in antigen presentation, dendritic cell biology, the innate response and immunosuppressive mechanisms, and emerging strategies for manipulation of the immune system for therapeutic benefit that have realized success in neuroblastoma, leukemia, melanoma, lung cancer, and allogeneic transplantation. Early successes as well as failures will be highlighted to provide a snapshot of the state of clinical immunotherapy with an eye to future possibilities such as combination therapies, adoptive T-cell transfer, and the retargeting of immune cells via T-cell receptor engineering.
ContentsPart I Immune Activation, Suppression and Manipulation of the Immune Antitumor ResponseMyeloid-Derived Suppressor Cells in Cancer.....Christos E. Kyriakopoulos, Alberto J. Montero, and Claudia Marcela Diaz-MonteroThe Role of B Cells in Shaping the Antitumor Immune Response......Yu Zhang, Taylor H. Schreiber, and Joseph D. RosenblattHeat-Shock Protein-Based Cancer Immunotherapy.....Taylor H. SchreiberActivation of NK Cell Responses and Immunotherapy of Cancer......George J. WeinerInduction of Tumor Immunity by Targeted Inhibition of Nonsense-Mediated mRNA Decay.....Eli GilboaEmploying T Cell Homeostasis as an Antitumor Strategy.....Shawn M. Jensen, Christopher C. Paustain, and Bernard A. FoxAdoptive Cell Therapy of Systemic Metastases Using erbB-2-Specific T Cells Redirected with a Chimeric Antibody-Based Receptor.....Dinorah Friedmann-Morvinski, Tova Waks, Assaf Marcus, and Zelig EshharPart II Evolving Clinical Immunotherapeutic StrategiesImmunotherapy in Renal Cell Carcinoma.....Jennifer Cudris and Jaime R. MerchanAdoptive T-Cell Transfer as a Clinical Antitumor Strategy for Hematologic Malignancies......Aaron P. Rapoport and Nadia IjazBifunctional Antibodies: Preclinical and Clinical Applications.....Casey W. Shuptrine and Louis M. WeinerClinical Development of Antibody-Fusion Proteins for Cancer Therapy.....Kory L. Alderson, Amy K. Erbe, Margaret Boyden, and Paul M. SondelImmunologic Outcomes of Allogeneic Stem Cell Transplantation: Graft-Versus-Host and Graft-Versus-Leukemia Responses and Implications for Future Therapy.....Lazaros J. Lekakis and Krishna V. KomanduriThe Immune System in Head and Neck Squamous Cell Carcinoma: Interactions and Therapeutic Opportunities.....Paolo Serafini and Donald T. WeedT Cell Co-regulatory Signals and Their Role in Cancer Therapy......Eitan R. Friedman, Lynn Feun, Pasquale Benedetto, and Joseph D. RosenblattAssessment of Immune Response in Biotherapy Trials and Clinical Endpoints.....Theresa L. WhitesideIndex
| Erscheint lt. Verlag | 25.10.2013 |
|---|---|
| Reihe/Serie | Current Cancer Research | Current Cancer Research |
| Zusatzinfo | IX, 371 p. 35 illus., 29 illus. in color. |
| Verlagsort | New York |
| Sprache | englisch |
| Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie | |
| Studium ► 1. Studienabschnitt (Vorklinik) ► Biochemie / Molekularbiologie | |
| Schlagworte | Antibody • Cancer • immunology • immunotherapy • T-cell • Tumor |
| ISBN-10 | 1-4614-8809-5 / 1461488095 |
| ISBN-13 | 978-1-4614-8809-5 / 9781461488095 |
| Haben Sie eine Frage zum Produkt? |
PDF (Wasserzeichen)Größe: 8,5 MB
DRM: Digitales Wasserzeichen
Dieses eBook enthält ein digitales Wasserzeichen und ist damit für Sie personalisiert. Bei einer missbräuchlichen Weitergabe des eBooks an Dritte ist eine Rückverfolgung an die Quelle möglich.
Dateiformat: PDF (Portable Document Format)
Mit einem festen Seitenlayout eignet sich die PDF besonders für Fachbücher mit Spalten, Tabellen und Abbildungen. Eine PDF kann auf fast allen Geräten angezeigt werden, ist aber für kleine Displays (Smartphone, eReader) nur eingeschränkt geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen dafür einen PDF-Viewer - z.B. den Adobe Reader oder Adobe Digital Editions.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen dafür einen PDF-Viewer - z.B. die kostenlose Adobe Digital Editions-App.
Zusätzliches Feature: Online Lesen
Dieses eBook können Sie zusätzlich zum Download auch online im Webbrowser lesen.
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich
